A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Cinolazepam
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Roflumilast
Roflumilast may increase the immunosuppressive activities of Hydrocortisone butyrate.
Cinolazepam
Difluocortolone
The risk or severity of adverse effects can be increased when Difluocortolone is combined with Hydrocortisone butyrate.
Cinolazepam
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydrocortisone butyrate.
Cinolazepam
Clobetasol
The risk or severity of adverse effects can be increased when Clobetasol is combined with Hydrocortisone butyrate.
Cinolazepam
Fluocortolone
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Hydrocortisone butyrate.
Cinolazepam
Bleselumab
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Bleselumab.
Cinolazepam
Rozanolixizumab
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Rozanolixizumab.
Cinolazepam
Risankizumab
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Risankizumab.
Cinolazepam
Hydrocortisone succinate
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Hydrocortisone succinate.
Cinolazepam
Mometasone furoate
The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Hydrocortisone butyrate.
Cinolazepam
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Hydrocortisone butyrate.
Cinolazepam
Fluclorolone
The risk or severity of adverse effects can be increased when Fluclorolone is combined with Hydrocortisone butyrate.
Cinolazepam
Cloprednol
The risk or severity of adverse effects can be increased when Cloprednol is combined with Hydrocortisone butyrate.
Cinolazepam
Fluperolone
The risk or severity of adverse effects can be increased when Fluperolone is combined with Hydrocortisone butyrate.
Cinolazepam
Begelomab
The risk or severity of adverse effects can be increased when Begelomab is combined with Hydrocortisone butyrate.
Cinolazepam
Fluocortin
The risk or severity of adverse effects can be increased when Fluocortin is combined with Hydrocortisone butyrate.
Cinolazepam
Prednylidene
The risk or severity of adverse effects can be increased when Prednylidene is combined with Hydrocortisone butyrate.
Cinolazepam
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Hydrocortisone butyrate.
Cinolazepam
Hypericin
The risk or severity of adverse effects can be increased when Hypericin is combined with Hydrocortisone butyrate.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3